文献速递角膜与眼表疾病

维生素D对圆锥角膜进展的影响

The Effects of Vitamin D on Keratoconus Progression.
PubMed 文献 · Am J Ophthalmol · 2025-04-15

这项前瞻性、干预性单中心研究纳入40例(年龄12.2-19.9岁)合并维生素D不足(<30 ng/mL)的圆锥角膜青少年患者,按标准治疗补充维生素D 6个月并随访12个月。结果显示65%患者(75%患眼)在12个月内最大角膜曲率进展小于1屈光度而保持稳定,血浆维生素D结合蛋白表达上调,外周白细胞VDR和CD14表达增加,炎症和血小板活化通路下调。

要点

  • 40例合并维生素D不足的圆锥角膜青少年补充维生素D 6个月后,65%患者(75%患眼)在12个月内最大角膜曲率进展小于1屈光度。
  • 补充维生素D后血浆维生素D结合蛋白表达上调,外周白细胞VDR和CD14表达增加。
  • 应答者RNA测序显示炎症和血小板活化通路下调、蛋白聚糖代谢/生物合成富集上调。

核心结论

  • 研究结果支持以下假说:补充维生素D可能通过调节全身炎症、抑制胶原降解和促进蛋白聚糖合成来影响维生素D不足的青少年圆锥角膜患者的疾病进展。
  • 研究结果强烈提示圆锥角膜可能是全身性疾病的一种眼部表现。

研究设计与样本

  • 前瞻性、干预性单中心研究,纳入40例(年龄范围12.2-19.9岁)同时患有圆锥角膜和维生素D不足(<30 ng/mL)的患者。
  • 按标准治疗补充维生素D 6个月,随访12个月,每次访视测量最佳矫正视力、最大角膜曲率和最薄角膜厚度。
  • 在第0个月和第6个月采集血样,用ELISA或实时聚合酶链反应检测维生素D水平和全身炎症、胶原降解、氧化应激生物标志物;对20例患者在0个月和6个月进行全RNA测序。

主要发现

  • 总体65%的患者(75%的患眼)在12个月后保持稳定,即最大角膜曲率进展小于1屈光度。
  • 最佳矫正视力、最大角膜曲率和最薄角膜厚度在12个月观察期内保持稳定。
  • 血浆ELISA显示维生素D上调维生素D结合蛋白的表达。
  • 外周白细胞qPCR显示VDR和CD14表达增加,而参与维生素D活化/失活的主要酶类无变化。
  • ELISA和qPCR显示胶原降解和胶原交联受到调节;亚组RNA测序显示对维生素D治疗的反应存在差异,应答者炎症和血小板活化通路下调、蛋白聚糖代谢/生物合成富集上调。

关键数值与推荐

  • 主要结局为整个研究期间最大角膜曲率进展小于1屈光度(即稳定患者)的患者百分比,结果为65%的患者(75%的患眼)保持稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to assess whether vitamin D (Vit D) supplementation affects local disease progression, as well as systemic inflammation, collagen degradation, and oxidative stress in adolescents affected by keratoconus (KC) and Vit D deficiency. DESIGN: Prospective, interventional single-center study. SUBJECTS: Forty patients (age range, 12.2-19.9) presenting with both KC and Vit D insufficiency (<30 ng/mL) were included in the study. METHODS: Vit D was prescribed for 6 months as per standard of care. Follow-up visits were scheduled for 12 months. Each visit included the measurement of best spectacle-corrected visual acuity, maximal keratometry (Kmax), and thinnest corneal thickness. Blood samples were collected at month 0 and month 6 to measure Vit D levels and systemic biomarkers of inflammation, collagen degradation, and oxidative stress by ELISA or real-time polymerase chain reaction; full RNA sequencing was performed on 20 patients at month 0 and month 6. MAIN OUTCOME MEASURES: The primary outcome of the study was the percentage of patients with a Kmax progression less than 1 diopter (D) throughout the entire study (ie, stable patients). RESULTS: Overall, 65% of patients remained stable (75% of eyes) after 12 months. Specifically, best spectacle-corrected visual acuity, Kmax, and thinnest corneal thickness rates remained stable during the 12-month observational period. ELISA performed on blood plasma showed that Vit D upregulated the expression of Vit D binding protein. QPCR performed on peripheral leukocytes showed an increase in the expression of VDR and CD14 with no changes in the principal enzymes involved in Vit D activation/deactivation. ELISA and qPCR showed the modulation of collagen degradation and collagen crosslinking. Subgroup analysis with RNA sequencing showed differential response to Vit D treatment. Responder patients showed downregulation in inflammatory and platelet activation pathways, and upregulation of proteoglycan metabolism/biosynthesis enrichment. CONCLUSIONS: Our findings support the hypothesis that Vit D supplementation can affect KC progression in adolescent patients with Vit D insufficiency possibly through the modulation of systemic inflammation, inhibition of collagen degradation, and promotion of proteoglycan synthesis. Our results strongly suggest that KC may be the ocular manifestation of a systemic disorder.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bartolomeo N, Pederzolli M, Palombella S, et al. The Effects of Vitamin D on Keratoconus Progression. Am J Ophthalmol. 2025. PMID: 40245974. doi:10.1016/j.ajo.2025.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。